This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Cassava (SAVA) Down as Quanterix Issues Statement on AD Study
by Zacks Equity Research
Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.
Cassava (SAVA) Responds to Charges Against its Integrity in AD Study
by Zacks Equity Research
Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.
Cassava (SAVA) Stock Up on Alzheimer's Candidate Update
by Zacks Equity Research
Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
Cassava Sciences (SAVA) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $79.65 in the latest trading session, marking a +1.34% move from the prior day.
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?
by Aditi Saraogi
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $34.85, marking a -0.68% move from the previous day.
Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SAVA) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences
A Year Into the COVID-19 Pandemic: 5 Stock Winners
by Sweta Killa
Though the U.S. economy is far from pre-pandemic levels, it has shown solid improvement. Meanwhile, the stock market has strongly bounced back and reached new milestones.
Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why
by Zacks Equity Research
Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SAVA) Outperforming Other Medical Stocks This Year?
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.
Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.
Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.